Reckitt share price slips in early London trade as investors eye dividend payout and March results
9 February 2026

Reckitt share price slips in early London trade as investors eye dividend payout and March results

London, Feb 9, 2026, 08:28 GMT — Regular session

  • Reckitt slipped roughly 0.6% shortly after the open.
  • The FTSE 100 edged about 0.3% higher as trading began.
  • Reckitt is set to present at CAGNY on Feb. 19, and full-year earnings drop March 5.

Reckitt Benckiser Group plc slipped 0.6% to 6,364 pence as of 0827 GMT on Monday. Shares moved between 6,358 and 6,434 pence, the latter level touching its 52-week high.

Investors are watching closely as Reckitt prepares for a hefty cash payout following the sale of its Essential Home unit. A special dividend of 235 pence per share lands on Feb. 20, paired with a 24-for-25 share consolidation — a standard step to adjust the share count after such a large distribution knocks the price lower.

Reckitt plans to release full-year results on March 5, followed by an investor presentation at the London Stock Exchange at 0830 GMT. After the portfolio reshuffle, many investors will be zeroed in on guidance for 2026 margins and costs.

The FTSE 100 in London edged up in the morning, sticking just above 10,400. NatWest slipped early on, and Unilever also dipped, Investing.com showed.

European stocks opened higher, with the STOXX 600 adding 0.5% at 0809 GMT. Investors looked to regain some footing after last week’s swings, sparked partly by uncertainty over returns from hefty bets on artificial intelligence.

Global signals leaned positive as well. Japan’s Nikkei notched new records following Prime Minister Sanae Takaichi’s election victory. FTSE futures added 0.4%, according to Reuters. Investors are eyeing U.S. jobs, retail sales, and inflation figures set for release this week—these numbers could sway expectations for rate cuts.

Some broker skepticism lingers. Last month, RBC Capital Markets lowered its rating on Reckitt to “sector perform” and trimmed the price target to 62 pounds, citing unfinished forecasts and uncertainty around 2026 margins as well as ongoing litigation risk. “Our new forecasts for Reckitt are not the finished article,” RBC said. Investing.com

Reckitt’s been using buybacks to boost returns, too. On Feb. 2, the company confirmed it wrapped up the second tranche of its 1 billion pound share buyback program, first unveiled in July 2025.

Still, risks haven’t gone away. Lawsuits in the U.S. targeting specialized preterm infant formula remain a concern. Last year, a judge in Missouri tossed a verdict, accusing defense lawyers for Abbott and Reckitt’s Mead Johnson of misconduct and granting a new trial. Both firms plan to appeal.

Another milestone lands next week: Reckitt’s CEO Kris Licht and CFO Shannon Eisenhardt are set to appear at the CAGNY conference in Orlando on Feb. 19. Their presentation, according to the company, will be webcast from 1500 to 1545 GMT.

So traders are back where they’ve been before: waiting on the company to back up the narrative with actual figures and guidance. All eyes on Reckitt’s full-year results, set for March 5.

Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

AerCap

NYSE: AER 95 / 100
#2 BUY

Uber

NYSE: UBER 93 / 100
#3 BUY ON WEAKNESS

Taiwan Semiconductor

NYSE: TSM 91 / 100
#4 ACCUMULATE

AIG

NYSE: AIG 88 / 100
#5 BUY THE RESET

Ferguson

NYSE: FERG 86 / 100
View full portfolio
Editorial model selection. Not personalised advice.
FedEx joins Advent in $9.2 billion InPost buyout to take parcel locker group private
Previous Story

FedEx joins Advent in $9.2 billion InPost buyout to take parcel locker group private

GSK share price hovers near a 52-week high as COPD approval, U.S. drug discounts come into view
Next Story

GSK share price hovers near a 52-week high as COPD approval, U.S. drug discounts come into view